Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2012

Open Access 01-06-2012 | Research article

Exercise training in pulmonary arterial hypertension associated with connective tissue diseases

Authors: Ekkehard Grünig, Felicitas Maier, Nicola Ehlken, Christine Fischer, Mona Lichtblau, Norbert Blank, Christoph Fiehn, Frank Stöckl, Felix Prange, Gerd Staehler, Frank Reichenberger, Henning Tiede, Michael Halank, Hans-Jürgen Seyfarth, Simone Wagner, Christian Nagel

Published in: Arthritis Research & Therapy | Issue 3/2012

Login to get access

Abstract

Introduction

The objective of this prospective study was to assess short- and long-term efficacy of exercise training (ET) as add-on to medical therapy in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-APAH).

Methods

Patients with invasively confirmed CTD-APAH received ET in-hospital for 3 weeks and continued at home for 12 weeks. Efficacy parameters have been evaluated at baseline and after 15 weeks by blinded-observers. Survival rate has been evaluated in a follow-up period of 2.9 ± 1.9 years.

Results

Twenty-one consecutive patients were included and assessed at baseline, and after 3 weeks, 14 after 15 weeks. Patients significantly improved the mean distance walked in 6 minutes compared to baseline by 67 ± 52 meters after 3 weeks (p < 0.001) and by 71 ± 35 meters after 15 weeks (p = 0.003), scores of quality of life (p < 0.05), heart rate at rest, peak oxygen consumption, oxygen saturation and maximal workload. Systolic pulmonary artery pressure and diastolic systemic blood pressure improved significantly after 3 weeks of ET. The 1- and 2-year overall-survival rates were 100%, the 3-year survival 73%. In one patient lung transplantation was performed 6 months after ET.

Conclusion

ET as add-on to medical therapy is highly effective in patients with CTD-APAH to improve work capacity, quality of life and further prognostic relevant parameters and possibly improves the 1-, 2- and 3-year survival rate. Further randomized controlled studies are needed to confirm these results.

Trial registration

ClinicalTrials.gov: NCT00491309.
Appendix
Available only for authorised users
Literature
1.
go back to reference Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG): Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009, 30: 2493-537.CrossRefPubMed Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG): Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009, 30: 2493-537.CrossRefPubMed
2.
go back to reference Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003, 62: 1088-93. 10.1136/ard.62.11.1088.PubMedCentralCrossRefPubMed Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003, 62: 1088-93. 10.1136/ard.62.11.1088.PubMedCentralCrossRefPubMed
3.
go back to reference Li EK, Tam LS: Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol. 1999, 26: 1923-29.PubMed Li EK, Tam LS: Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol. 1999, 26: 1923-29.PubMed
4.
go back to reference Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB: Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol. 2006, 25: 866-72. 10.1007/s10067-006-0206-5.CrossRefPubMed Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB: Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol. 2006, 25: 866-72. 10.1007/s10067-006-0206-5.CrossRefPubMed
5.
go back to reference Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC: Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999, 42: 899-909. 10.1002/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L.CrossRefPubMed Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC: Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999, 42: 899-909. 10.1002/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L.CrossRefPubMed
6.
go back to reference Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G: Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006, 173: 1023-30. 10.1164/rccm.200510-1668OC.CrossRefPubMed Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G: Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006, 173: 1023-30. 10.1164/rccm.200510-1668OC.CrossRefPubMed
7.
go back to reference Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT: Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010, 138: 1383-94. 10.1378/chest.10-0260.PubMedCentralCrossRefPubMed Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT: Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010, 138: 1383-94. 10.1378/chest.10-0260.PubMedCentralCrossRefPubMed
8.
go back to reference Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators: The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012, 71: 249-52. 10.1136/annrheumdis-2011-200265.CrossRefPubMed Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators: The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012, 71: 249-52. 10.1136/annrheumdis-2011-200265.CrossRefPubMed
9.
go back to reference Condliffe R, Kiely D, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins D, Hughes RJ, Pepke-Zaba J, Coghlan JG: Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009, 179: 91-92.CrossRef Condliffe R, Kiely D, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins D, Hughes RJ, Pepke-Zaba J, Coghlan JG: Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009, 179: 91-92.CrossRef
10.
go back to reference Goldberg A: Pulmonary Arterial Hypertension in Connective Tissue Diseases. Cardiol Rev. 2010, 18: 85-88. 10.1097/CRD.0b013e3181cbcde7.CrossRefPubMed Goldberg A: Pulmonary Arterial Hypertension in Connective Tissue Diseases. Cardiol Rev. 2010, 18: 85-88. 10.1097/CRD.0b013e3181cbcde7.CrossRefPubMed
11.
go back to reference Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002, 346: 896-903. 10.1056/NEJMoa012212.CrossRefPubMed Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002, 346: 896-903. 10.1056/NEJMoa012212.CrossRefPubMed
12.
go back to reference Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008, 117: 3010-19. 10.1161/CIRCULATIONAHA.107.742510.CrossRefPubMed Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008, 117: 3010-19. 10.1161/CIRCULATIONAHA.107.742510.CrossRefPubMed
13.
go back to reference Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E: Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006, 114: 1482-89. 10.1161/CIRCULATIONAHA.106.618397.CrossRefPubMed Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E: Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006, 114: 1482-89. 10.1161/CIRCULATIONAHA.106.618397.CrossRefPubMed
14.
go back to reference Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Olschewski H, Halank M: Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration. 2011, 81: 394-401. 10.1159/000322475.CrossRefPubMed Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Olschewski H, Halank M: Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration. 2011, 81: 394-401. 10.1159/000322475.CrossRefPubMed
15.
go back to reference Grünig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Sorichter S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R, Nagel C: Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J. Grünig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Staehler G, Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Sorichter S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R, Nagel C: Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J.
16.
go back to reference Carvalho MR, Sato EI, Tebexreni AS, Heidecher RT, Schenkman S, Neto TL: Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum. 2005, 53: 838-44. 10.1002/art.21605.CrossRefPubMed Carvalho MR, Sato EI, Tebexreni AS, Heidecher RT, Schenkman S, Neto TL: Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum. 2005, 53: 838-44. 10.1002/art.21605.CrossRefPubMed
17.
go back to reference Pinto ALS, Oliveira NC, Gualano B, Christmann RB, Painelli VS, Artioli GG, Prado DM, Lima FR: Efficacy and safety of concurrent training in systemic sclerosis. J Strength Cond Res. 2011, 25: 1423-28. 10.1519/JSC.0b013e3181d6858b.CrossRefPubMed Pinto ALS, Oliveira NC, Gualano B, Christmann RB, Painelli VS, Artioli GG, Prado DM, Lima FR: Efficacy and safety of concurrent training in systemic sclerosis. J Strength Cond Res. 2011, 25: 1423-28. 10.1519/JSC.0b013e3181d6858b.CrossRefPubMed
18.
go back to reference Schouffoer AA, Ninaber MK, Beaart-van de Voorde LJ, van der Giesen FJ, de Jong Z, Stolk J, Voskuyl AE, Scherptong RW, van Laar JM, Schuerwegh AJ, Huizinga TW, Vlieland TP: Randomized comparison of a multidisciplinary team care program with usual care in patients with systemic sclerosis. Arthritis Care Res. 2011, 63: 909-17. 10.1002/acr.20448.CrossRef Schouffoer AA, Ninaber MK, Beaart-van de Voorde LJ, van der Giesen FJ, de Jong Z, Stolk J, Voskuyl AE, Scherptong RW, van Laar JM, Schuerwegh AJ, Huizinga TW, Vlieland TP: Randomized comparison of a multidisciplinary team care program with usual care in patients with systemic sclerosis. Arthritis Care Res. 2011, 63: 909-17. 10.1002/acr.20448.CrossRef
19.
go back to reference Antonioli CM, Bua G, Frigè A, Prandini K, Radici S, Scarsi M, Danieli E, Malvicini A, Airo P: An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility. Clin Rheumatol. 2009, 28: 159-65. 10.1007/s10067-008-1006-x.CrossRefPubMed Antonioli CM, Bua G, Frigè A, Prandini K, Radici S, Scarsi M, Danieli E, Malvicini A, Airo P: An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility. Clin Rheumatol. 2009, 28: 159-65. 10.1007/s10067-008-1006-x.CrossRefPubMed
20.
go back to reference Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW: Effect of encouragement on walking test performance. Thorax. 1984, 39: 818-22. 10.1136/thx.39.11.818.PubMedCentralCrossRefPubMed Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW: Effect of encouragement on walking test performance. Thorax. 1984, 39: 818-22. 10.1136/thx.39.11.818.PubMedCentralCrossRefPubMed
21.
go back to reference Borg G: Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982, 14: 377-81.PubMed Borg G: Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982, 14: 377-81.PubMed
22.
go back to reference Ware J, Sherbourne C: The MOS 36-Item Short-Form Health Survey (SF-36): I. conceptual framework and item selection. Medical Care. 1992, 30: 473-83. 10.1097/00005650-199206000-00002.CrossRefPubMed Ware J, Sherbourne C: The MOS 36-Item Short-Form Health Survey (SF-36): I. conceptual framework and item selection. Medical Care. 1992, 30: 473-83. 10.1097/00005650-199206000-00002.CrossRefPubMed
23.
go back to reference Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, Riemekasten G, De Vita S, Morganti A, Dölberg M, Berkani O, Guillevin L, TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators: Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008, 67: 1222-28.PubMedCentralCrossRefPubMed Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, Riemekasten G, De Vita S, Morganti A, Dölberg M, Berkani O, Guillevin L, TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators: Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008, 67: 1222-28.PubMedCentralCrossRefPubMed
24.
go back to reference Hachulla E, Launay D, Yaici A, Berezne A, de Groote P, Sitbon O, Mouthon L, Guillevin L, Hatron PY, Simonneau G, Clerson P, Humbert M, French PAH-SSc Network: Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology. 2010, 49: 940-944. 10.1093/rheumatology/kep449.CrossRefPubMed Hachulla E, Launay D, Yaici A, Berezne A, de Groote P, Sitbon O, Mouthon L, Guillevin L, Hatron PY, Simonneau G, Clerson P, Humbert M, French PAH-SSc Network: Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology. 2010, 49: 940-944. 10.1093/rheumatology/kep449.CrossRefPubMed
25.
go back to reference Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G: Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010, 122: 156-63. 10.1161/CIRCULATIONAHA.109.911818.CrossRefPubMed Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G: Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010, 122: 156-63. 10.1161/CIRCULATIONAHA.109.911818.CrossRefPubMed
26.
go back to reference Johnson SR, Granton JT: Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev. 2011, 20: 277-86. 10.1183/09059180.00003811.CrossRefPubMed Johnson SR, Granton JT: Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev. 2011, 20: 277-86. 10.1183/09059180.00003811.CrossRefPubMed
27.
go back to reference Impens AJ, Wangkaew S, Seibold JR: The 6-minute walk test in scleroderma--how measuring everything measures nothing. Rheumatology. 2008, 47: 68-69. 10.1093/rheumatology/kem296.CrossRef Impens AJ, Wangkaew S, Seibold JR: The 6-minute walk test in scleroderma--how measuring everything measures nothing. Rheumatology. 2008, 47: 68-69. 10.1093/rheumatology/kem296.CrossRef
Metadata
Title
Exercise training in pulmonary arterial hypertension associated with connective tissue diseases
Authors
Ekkehard Grünig
Felicitas Maier
Nicola Ehlken
Christine Fischer
Mona Lichtblau
Norbert Blank
Christoph Fiehn
Frank Stöckl
Felix Prange
Gerd Staehler
Frank Reichenberger
Henning Tiede
Michael Halank
Hans-Jürgen Seyfarth
Simone Wagner
Christian Nagel
Publication date
01-06-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3883

Other articles of this Issue 3/2012

Arthritis Research & Therapy 3/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.